Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis

Clinical Genitourinary Cancer

Volumn 15, Issue 2, 2017, Pages 300-305

  Nayan, Madhur ^a   Finelli, Antonio ^a   Jewett, Michael A S ^a   Juurlink, David N ^b   Austin, Peter C ^c,d,e   Kulkarni, Girish S ^a   Hamilton, Robert J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e Canada   (Canada)

Author keywords

Disease progression; Humans; Nephrectomy; Renal cell carcinoma; Survival

Indexed keywords

INSULIN; METFORMIN; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PROPENSITY SCORE; RADICAL NEPHRECTOMY; RETROSPECTIVE STUDY; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; NEPHRECTOMY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DIABETES MELLITUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY NEOPLASMS; MALE; METFORMIN; MIDDLE AGED; NEPHRECTOMY; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84979503139     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.06.008     Document Type: Article

References (35)

1. 1 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
2. 2 Znaor, A., Lortet-Tieulent, J., Laversanne, M., Jemal, A., Bray, F., International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol 67 (2015), 519–530.
3. 3 Chow, W.H., Dong, L.M., Devesa, S.S., Epidemiology and risk factors for kidney cancer: nature reviews. Urology 7 (2010), 245–257.
4. 4 De, P., Otterstatter, M.C., Semenciw, R., Ellison, L.F., Marrett, L.D., Dryer, D., Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986-2007. Cancer Causes Control 25 (2014), 1271–1281.
5. 5 Stephenson, A.J., Chetner, M.P., Rourke, K., et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172 (2004), 58–62.
6. 6 Garber, A.J., Abrahamson, M.J., Barzilay, J.I., et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement—executive summary. Endocr Pract 19 (2013), 536–557.
7. 7 Margel, D., Urbach, D.R., Lipscombe, L.L., et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31 (2013), 3069–3075.
8. 8 Nayan, M., Bhindi, B., Julie, L.Y., et al. The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urol Oncol 33 (2015), 386.e7–386.e13.
9. 9 Hakimi, A.A., Chen, L., Kim, P.H., et al. The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma. Can Urol Assoc J 7 (2013), E687–E691.
10. 10 Haake, S.M., Brooks, S.A., Welsh, E., et al. Molecular subtypes of clear cell renal cell carcinoma: impact of diabetes mellitus, metformin, and immunotherapy on patient outcomes. J Clin Oncol, 32(suppl), 2014, 5s abstract 4579.
11. 11 Khimani, F., Shah, N., Curley, B.F., Newton, M.D., Hogan, T.F., Monga, M., Metformin use and renal cell cancer outcomes among patients with diabetes. J Clin Oncol, 32(suppl 4), 2014 abstract 543.
12. 12 Shah, N., Khimani, F., Curley, B.F., et al. Metformin use and survival in diabetic patients with renal cell carcinoma (RCC). J Clin Oncol, 32(suppl), 2014 abstract e15612.
13. 13 Psutka, S.P., Boorjian, S.A., Lohse, C.M., et al. The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Urol Oncol 33 (2015), 67.e15–67.e23.
14. 14 Cheng, J.J.S., Li, H., Tan, H.S., et al. Metformin use in relation with survival outcomes of patients with renal cell carcinoma. Clin Genitourin Cancer 14 (2016), 168–175.
15. 15 Clarke, E., Marrett, L., Kreiger, N., Appendix 3 (c): Cancer registration in Ontario: a computer approach. Jensen, O.M., Parkin, D.M., MacLennan, R., Muir, C.S., Skeet, R.G., (eds.) Cancer Registration: Principles and Methods. IARC Scientific Publication No. 95, 1991, International Agency for Research on Cancer, Lyon, France, 246–257.
16. 16 Austin, P.C., The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33 (2014), 1242–1258.
17. 17 Austin, P.C., Mamdani, M.M., A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 25 (2006), 2084–2106.
18. 18 Austin, P.C., Stuart, E.A., Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34 (2015), 3661–3679.
19. 19 Brookhart, M.A., Wyss, R., Layton, J.B., Stürmer, T., Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 6 (2013), 604–611.
20. 20 Vaughan, A.S., Kelley, C.F., Luisi, N., del Rio, C., Sullivan, P.S., Rosenberg, E.S., An application of propensity score weighting to quantify the causal effect of rectal sexually transmitted infections on incident HIV among men who have sex with men. BMC Med Res Method, 15, 2015, 25.
21. 21 Cole, S.R., Hernán, M.A., Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 75 (2004), 45–49.
22. 22 Lin, D.Y., Wei, L.J., Ying, Z., Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 80 (1993), 557–572.
23. 23 Vavallo, A., Simone, S., Lucarelli, G., et al. Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine (Baltimore), 93, 2014, e183.
24. 24 Ha, Y.S., Kim, W.T., Yun, S.J., et al. Multi-institutional analysis of localized renal cell carcinoma that demonstrates the impact of diabetic status on prognosis after nephrectomy. Ann Surg Oncol 20 (2013), 3662–3668.
25. 25 Fleshner N, Joshua A. University Health Network, Toronto. A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for lower risk prostate cancer: the MAST (Metformin Active Surveillance Trial) study. ClinicalTrials.gov identifier NCT01864096. Available at: https://clinicaltrials.gov/ct2/show/NCT01864096. Accessed: October 17, 2015.
26. 26 MD Anderson Cancer Center. Temsirolimus in combination with metformin in patients with advanced cancers. ClinicalTrials.gov identifier NCT01529593. Available at: https://clinicaltrials.gov/ct2/show/NCT01529593. Accessed: October 17, 2015.
27. 27 Aljada, A., Mousa, S.A., Metformin and neoplasia: implications and indications. Pharmacol Ther 133 (2012), 108–115.
28. 28 Romaschin, A.D., Youssef, Y., Chow, T.-F.F., Yousef, G.M., Exploring the pathogenesis of renal cell carcinoma: pathway and bioinformatics analysis of dysregulated genes and proteins. Biol Chem 390 (2009), 125–135.
29. 29 Liu, J., Li, M., Song, B., et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 31 (2013), 264–270.
30. 30 Austin, P.C., Tu, J.V., Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality. J Clin Epidemiol 57 (2004), 1138–1146.
31. 31 Karakiewicz, P.I., Jeldres, C., Suardi, N., et al. Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J 2 (2008), 610–617.
32. 32 Aron, M., Nguyen, M.M., Stein, R.J., Gill, I.S., Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol 54 (2008), 133–142.
33. 33 Sterne, J.A., White, I.R., Carlin, J.B., et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ, 338, 2009, b2393.
34. 34 Lega, I.C., Austin, P.C., Gruneir, A., Goodwin, P.J., Rochon, P.A., Lipscombe, L.L., Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 36 (2013), 3018–3026.
35. 35 Leibovich, B.C., Lohse, C.M., Crispen, P.L., et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 183 (2010), 1309–1316.